CD274 and neoplasm: They found TMB alone showed a positive association with overall response rate (ORR) with nivolumab [OR (95% CI): 2.13 (1.26–3.60), p < 0.05] regardless of baseline tumor PD-L1 expression, although the tail of the curve showed a longer survival benefit in patients with both high TMB and PD-L1 expression ≥1% [22].